-
Name
Urokinase
- EINECS 232-917-9
- CAS No. 9039-53-6
- Density
- Solubility Reconstitute in water at 100µg/ml
- Melting Point
- Formula Unspecified
- Boiling Point
- Molecular Weight 0
- Flash Point
- Transport Information
- Appearance
- Safety
- Risk Codes
-
Molecular Structure
- Hazard Symbols B
- Synonyms Abbokinase;Actosolv;Breokinase;Double-chainurokinase-type plasminogen activator;E.C. 3.4.21.31;E.C. 3.4.21.73;E.C.3.4.99.26;Persolv;Plasminokinase, urinary;Pro-HGF convertase;Pro-hepatocytegrowth factor convertase;Purochin;Two-chain urokinase;Two-chainurokinase-type plasminogen activator;Ukidan;Urokinase;Urokinase plasminogenactivator;Urokinase-like plasminogen activator;Urokinase-type plasminogenactivator;Uronase;Win 22005;Win-Kinase;
- PSA 0.00000
- LogP 0.00000
Urokinase Consensus Reports
Reported in EPA TSCA Inventory.
Urokinase Specification
The systematic name of Urokinase is Kinase (enzyme-activating), uro-. With the CAS registry number 9039-53-6, it is also named as Abbokinase. The product's classification codes are Drug / Therapeutic Agent; Plasminogen activator; Plasminogen Activators; Reproductive Effect; TSCA Flag XU [Exempt from reporting under the Inventory Update Rule], and the other registry numbers are 139639-24-0; 37211-64-6. Besides, it is white powder, which should be sealed in brown glass bottle at 2-8 °C. This chemical is a serine protease. In addition, The most important inhibitors of this chemical are the serpins plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2).
Preparation and Uses of Urokinase: this chemical was originally isolated from human urine. Additionally, this product can be used as anticancer agents. Moreover, it has been used clinically in the treatment of severe or massive deep venous thrombosis, pulmonary embolism, myocardial infarction, and occluded intravenous or dialysis cannulas as a thrombolytic agent.
The toxicity data is as follows:
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LD50 | intravenous | > 909ug/kg (0.909mg/kg) | Drugs in Japan Vol. -, Pg. 164, 1990. | |
| mouse | LD50 | intravenous | > 3000ku/kg (3000000iu/kg) | Kiso to Rinsho. Clinical Report. Vol. 15, Pg. 514, 1981. | |
| mouse | LD50 | oral | > 2727ug/kg (2.727mg/kg) | Drugs in Japan Vol. -, Pg. 164, 1990. | |
| mouse | LD50 | subcutaneous | > 2727ug/kg (2.727mg/kg) | Drugs in Japan Vol. -, Pg. 164, 1990. | |
| rat | LD50 | intravenous | > 3000ku/kg (3000000iu/kg) | Kiso to Rinsho. Clinical Report. Vol. 15, Pg. 514, 1981. | |
| rat | LD50 | oral | > 2727ug/kg (2.727mg/kg) | Drugs in Japan Vol. -, Pg. 164, 1990. | |
| rat | LD50 | subcutaneous | > 2727ug/kg (2.727mg/kg) | Drugs in Japan Vol. -, Pg. 164, 1990. |
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View